INT Awarded with Phase I SBIR Grant Funding from the NIH

Innovative NeuroTechnologies, Inc. (INT) in collaboration with James W. Larrick, M.D., Ph.D. of Panorama Research, Inc. (PRI) have been awarded $293,000 Phase I grant from the National Institute of Health (NIH) Small Business Innovation Research (SBIR) program to conduct preliminary "proof-of-concept" animal efficacy studies for the N-terminal Tau monoclonal antibody (i.e., INT-1 mAb) in relevant transgenic mouse models for tauopathies.  The group has proposed to develop a novel therapeutic approach for neurodegenerative tauopathies like Alzheimer's disease (AD) with the use a recombinant adenoassociated viral (AAV) vector to achieve long-term, stable delivery of the N-terminal (INT-1) mAb pass the blood-brain barrier (BBB) and into the affected neurons of the central nervous system (CNS).